Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to see whether the study drug, amivantamab, is an effective treatment for people with EGFR- or MET-amplified esophagogastric cancer. The researchers will also look at whether amivantamab is a safe treatment that causes few or mild side effects in participants.

Clinical Trial Description


Study Design

Related Conditions & MeSH terms

NCT number NCT05117931
Study type Interventional
Source Memorial Sloan Kettering Cancer Center
Contact Steven Maron, MD
Phone 646-888-6780
Email [email protected]
Status Not yet recruiting
Phase Phase 2
Start date November 30, 2021
Completion date November 2023

See also
  Status Clinical Trial Phase
Recruiting NCT04161781 - A Study of PET Scans With the Radioactive Tracer 18F-BMS-986229 in Patients With Esophageal, Stomach, or Gastroesophageal Junction Cancer
Completed NCT01803282 - Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Chemotherapy in Participants With Advanced Solid Tumors Phase 1
Withdrawn NCT02296671 - Personalized Therapy for Esophagogastric Cancer Using Thymidylate Synthase Genetic Markers Phase 2
Recruiting NCT04757363 - A Study of Nivolumab Combined With FOLFOX and Regorafenib in People Who Have HER2-Negative Esophagogastric Cancer Phase 2
Active, not recruiting NCT02023996 - PET Imaging With 89Zr-DFO-Trastuzumab in Esophagogastric Cancer N/A
Not yet recruiting NCT03760289 - DKN-01/Atezolizumab as Second Line Treatment of biliarY Tract Cancer and in combiNAtion or Not With Paclitaxel as Second Line treatMent of esophagogastrIC Cancer Phase 2
Completed NCT01167114 - STA-9090 in Previously Treated Patients With Advanced Esophagogastric Cancer Phase 2
Recruiting NCT03133650 - A Trial of a New Type of Photodynamic Therapy (VTP) in the Treatment of Patients With Cancer of the Esophagus Who Have Trouble Swallowing Phase 1
Not yet recruiting NCT04656041 - Folfox+Irinotecan+Chemort In Esophageal Cancer Phase 2